Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.06.2012 | review

What’s new in metastatic breast cancer?

verfasst von: Rupert Bartsch, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

Overall, breast cancer mortality has declined due to advances in systemic adjuvant treatment in recent years; still, metastatic breast cancer remains an incurable disease. Due to novel treatment options, however, survival was prolonged even in patients with advanced-stage disease. In hormone-receptor positive breast cancer, endocrine therapy is the mainstay of treatment. Currently, different strategies are being evaluated to overcome resistance to anti-hormonal interventions, with the aim to prolong the chemotherapy-free interval. In Her2-positive breast cancer, anti-Her2 targeted therapies such as trastuzumab or lapatinib have improved patients’ outcome. Further substances—antibodies or novel tyrosine-kinase inhibitors—will increase therapeutic options in the future. Limited progress was achieved in the triple-negative sub-type. Bevacizumab, a monoclonal antibody targeting the vascular endothelial growth factor, is currently the only biological agent available in this sub-type. In combination with paclitaxel or capecitabine, bevacizumab offers clinically meaningful activity in metastatic breast cancer patients. Other strategies, such as treatment with DNA-damaging agents or the inhibition of DNA-repair mechanisms were not successful so far in a general triple-negative population. This article reviews recent developments and future trends in the field of metastatic breast cancer.
Vorheriger Artikel Evolving strategies to overcome endocrine resistance in breast cancer
Nächster Artikel Surgical removal of the primary?—The role it plays in stage IV breast cancer
Literatur
1.
Brewster AM, Hortobagyi GN, Broglio KR, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. J Natl Cancer Inst. 2008;100(16):1179–83.CrossRefPubMed
2.
O’Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl. 3):20–9.CrossRefPubMed
3.
Beslija S, Bonneterre J, Burstein HJ, et al. Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009;20(11):1771–85.CrossRefPubMed
4.
Riggio M, Polo ML, Blaustein M, et al. PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer. Carcinogenesis 2012; [Epub ahead of print]. PMID: 22180571.
5.
Bartlett JMS, Brookes CL, van de Velde CJH, et al. Final results of a prospectively planned biomarker analysis: HER1-3 as predictive markers of benefit from early treatment with aromatase inhibitors versus tamoxifen in the TEAM pathology sub-study. Cancer Res. 2010;70(Suppl. 2):Abst. S2-4.
6.
Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538–46.CrossRefPubMed
7.
Osborne CK, Neven P, Dirix LY, et al. Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res. 2011;17(5):1147–59.CrossRefPubMed
8.
Baselga J, Semiglazov V, van Dam P, et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. J Clin Oncol. 2009;27(16):2630–7.CrossRefPubMed
9.
Baselga J, Campone M, Piccart M, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2011;[Epub ahead of print]. PMID: 22149876.
10.
Gianni L, Lladó A, Bianchi G, et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010;28(7):1131–7.CrossRefPubMed
11.
Schneeweiss A, Chia S, Hickish T, et al. Neoadjuvant pertuzumab and trastuzumab concurrent or sequential with an anthracycline-containing or concurrent with an anthracycline-free standard regimen: a randomized phase II study (TRYPHAENA). Cancer Res. 2011;71(Suppl. 3):Abst. S5-6.
12.
Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32.CrossRefPubMed
13.
Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19.CrossRefPubMed
14.
Burris III HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol. 2011;29(4):398–405.CrossRef
15.
Perez EA, Dirix L, Kocsis J, et al. Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized, multicenter, open-label phase 2 study (TDM4450G). Ann Oncol. 2010;21(Suppl. 8):LBA3.
16.
ClinicalTrials. http://​www.​clincialtrials.​gov.​ Accessed 2 Feb 2012.
17.
Cortés-Funes H, Mendiola C, Manso L, Ciruelos E. Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+ breast cancer. Breast Cancer Res. 2009;11(Suppl. 1):S19.CrossRefPubMed
18.
Martin M, Bonneterre J, Geyer Jr CE, et al. A Phase 2, Randomized, Open-Label, Study of Neratinib (HKI-272) vs lapatinib plus capecitabine for 2nd/3rd-line treatment of HER2+ locally advanced or metastatic breast cancer. Cancer Res. 2011;71(Suppl. 3):Abst. S5-7.
19.
Hickish T, Wheatley D, Lin N, et al. Use of BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor to treat patients with HER2-positive metastatic breast cancer after failure of treatment with trastuzumab. Cancer Res. 2009;96(Suppl. 3):Abst. 5060.CrossRef
20.
Gianni L, Bianchini G, Kiermaier A, et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): biomarker analyses of a 4-Arm randomized phase II study (NeoSphere) in patients (pts) with HER2-positive breast cancer (BC). Cancer Res. 2011;71(Suppl. 3):Abst. S5-1.
21.
Xu B, Guan Z-Z, Shen Z-Z, et al. Association of PTEN loss and PIK3CA mutations on outcome in HER2+ metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone. Cancer Res. 2011;71(Suppl. 3):Abst. S3-3.
22.
23.
Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate hypoxia-induceable factor 1α (HIF-1 α) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001;21(12):3995–4004.CrossRefPubMed
24.
Gianni L, Romieu G, Lichinitser M, et al. First results of AVEREL, a randomized phase III trial to evaluate bevacizumab (BEV) in combination with trastuzumab (H) + docetaxel (DOC) as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC). Cancer Res. 2011;71(Suppl. 3):Abst. S4-8.
25.
Bergh J, Greil R, Voytko N, et al. Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC). J Clin Oncol. 2010;28(Suppl. 18):Abst. LBA1010.
26.
Crown J, Dieras V, Staroslawska E, et al. Phase III trial of sunitinib (SU) in combination with capecitabine (C) versus C in previously treated advanced breast cancer (ABC). J Clin Oncol. 2010;28(Suppl. 18):Abst. LBA1011.
27.
Baselga J, Roche H, Costa F, et al. SOLTI-0701: a multinational double-blind, randomized phase 2b study evaluating the efficacy and safety of sorafenib compared to placebo when administered in combination with capecitabine in patients with locally advanced or metastatic breast cancer (BC). Cancer Res. 2009;69(Suppl. 24):Abst. 45.CrossRef
28.
Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res. 2006;8(4):R38.CrossRefPubMed
29.
Turner N, Tutt A, Ashworth A. Hallmarks of “BRCAness” in sporadic cancers. Nat Rev Cancer. 2004;4(10):814–9.CrossRefPubMed
30.
Gelmon KA, Hirte HW, Robidoux A, et al. Can we define tumors that will respond to PARP inhibitors? A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer. J Clin Oncol. 2010;25(Suppl. 18):Abst. 3002.
31.
Sirohi B, Arnedos M, Popat S, et al. Platinum-based chemotherapy in triple-negative breast cancer. Ann Oncol. 2009;19(11):1847–52.CrossRef
32.
Byrski T, Huzarski T, Dent R, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009:115(2):359–63.CrossRefPubMed
33.
Serra V, Markman B, Scaltriti M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008;68(19):8022–30.CrossRefPubMed
34.
Baselga J, Gomez P, Awada A, et al. The addition of cetuximab to cisplatin increases overall response rate (ORR) and progression free survival (PFS) in metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II study (BALI-1). Ann Oncol. 2010;21(Suppl. 8):Abst. 274O.
35.
Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998;351(9113):1393–6.CrossRefPubMed
36.
Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 2005;65(23):11118–28.CrossRefPubMed
37.
Citri A, Kochupurakkal BS, Yarden Y. The achilles heel of ErbB-2/HER2: regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle. 2004;3(1):51–60.CrossRefPubMed
38.
Modi S, Stopeck A, Linden H, et al. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab. Clin Cancer Res. 2011;17(15):5132–9.CrossRefPubMed
39.
Wiedermann U, Wiltschke C, Jasinska J, et al. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu-specific immune responses in patients with metastatic breast cancer: a phase I study. Breast Cancer Res Treat. 2010;119(3):673–83.CrossRefPubMed
40.
Mohebtash M, Tsang KY, Madan RA, et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2011;17(22):7164–73.CrossRefPubMed
41.
Lobell RB, Omer CA, Abrams MT, et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res. 2001;61(24):8758–68.
42.
Johnston SR, Semiglazov VF, Manikhas GM, et al. A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy. Breast Cancer Res Treat. 2008;110(2):327–35.CrossRefPubMed
Metadaten
Titel
What’s new in metastatic breast cancer?
verfasst von
Rupert Bartsch, MD
Publikationsdatum
01.06.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0004-5

Weitere Artikel der Ausgabe 2/2012

Breast cancer—advanced stage: “cure—still a long way to go?”

  • editorial

The role of Positron Emission Tomography/Computer Tomography (PET/CT) in the diagnosis, staging, characterization, and therapy of breast cancer

  • short review

Advanced breast cancer: new imaging techniques for detection of metastases

  • short review

Cellular immunotherapy for cancer. Past, present, future

  • editorial

Lung cancer screening: current evidence and recommendations

  • short review

The role of biomarkers in the choice of therapy in breast cancer

  • short review